In this article, we
describe the clinical picture and follow-up of two children diagnosed as suffering from pseudohypoaldosteronism when they were
infants, and it was later recognized as isolated aldosterone deficiency in both. We illustrate the clinical
differences between the two patients in terms of hydroelectrolytic balance,
laboratory data and growth. In fact, while the growth and hematological
parameters of the electrolytes and acid-base balance were normal in the first
patient, and also without treatment with fludrocortisone thanks to very high
renin activity, in the second patient, this treatment was vitally necessary tomaintain normal growth and biochemical data.
Despite the absence of a molecular analysis which could have confirmed this
diagnosis, we believe that the description of the clinical evolution of these
two cases from the moment of the incorrect diagnosis until the correct
diagnosis and action taken, could be useful to highlight the extreme clinical
variability of this rare disease.
References
[1]
White, P.C. (1994) Disorders of aldosterone biosynthesis and action. New England Journal of Medicine, 331, 250-257. http://dx.doi.org/10.1056/NEJM199407283310408
[2]
Miller, W.L. (2005) The adrenal cortex and its disorders. In: Brook, C., Clayton, P. and Brown, R., Eds., Brook’s Clinical Pediatric Endocrinology, 5th Edition, Blackwell Publishing, Malden, Massachussets, cp. 15, 293-351.
[3]
Kayes-Wandover, K.M., Tannin, G.M., Shulman, D., Peled, D., Jones, K.L., Karaviti, L. and White, P.C. (2001) Congenital hyperreninemic hypoaldosteronism unlinked to the aldosterone synthase (CYP11B2) gene. The Journal of Clinical Endocrinology & Metabolism, 86, 5379-5382. http://dx.doi.org/10.1210/jc.86.11.5379
[4]
Ulick, S., Wang, J.Z. and Morton, D.H. (1992) The biochemical phenotypes of two inborn errors in the biosynthesis of aldosterone. The Journal of Clinical Endocrinology & Metabolism, 74, 1415-1420.
http://dx.doi.org/10.1210/jc.74.6.1415
[5]
White, P.C. (2004) Aldosterone synthase deficiency and related disorders. Molecular and Cellular Endocrinology, 217, 81-87. http://dx.doi.org/10.1016/j.mce.2003.10.013
[6]
Lovas, K., Mc Farlane, I., Nguyen, H.H., Curran, S., Schwabe, J., Halsall, D., Bernhardt, R., Wallace, A.M. and Chatterjee, V.K. (2009) A novel CYP11B2 gene mutation in an Asian family with aldosterone synthase deficiency. The Journal of Clinical Endocrinology & Metabolism, 94, 914-919.
http://dx.doi.org/10.1210/jc.2008-1524
[7]
Choi, M.J. and Ziyadeh, F.N. (2008) The utility of the transtubular potassium gradient in the evaluation of hyperkalemia. Journal of the American Society of Nephrology, 19, 424-426.
http://dx.doi.org/10.1681/ASN.2007091017
[8]
White, P.C. and Bachega, T.A.S.S. (2012) Congenital adrenal hyperplasia due to 21 hydroxylase deficiency: From birth to adulthood. Seminars in Reproductive Medicine, 30, 400-409.
http://dx.doi.org/10.1055/s-0032-1324724
[9]
Saravanapandian, N., Paul, S. and Matthai, J. (2012) Pseudohypoaldosteronism type 1: A rare cause of severe dyselectrolytemia and cardiovascular collapse in neonates. Journal of Clinical Neonatology, 1, 224-226.
http://dx.doi.org/10.4103/2249-4847.106007
[10]
Throckmorton, D.G. and Bia, M.J. (1991) Pseudohypoaldosteronism: Report and discussion of the syndrome. The Yale Journal of Biology and Medicine, 64, 247-254.
[11]
Riepe, F.G. (2013) Pseudohypoaldosteronism. In: Maghnie, M., Loche, S., Cappa, M. Ghizzoni, L. and Lorini, R., Eds., Hormone Resistance and Hypersensitivity. From Genetics to Clinical Management. Endocrine Development, Basel, Karger, 24, 86-95.
[12]
Taymans, S.E., Pack, S., Pak, E., Torpy D.J., Zhuang, Z. and Stratakis, C.A. (1998) Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. The Journal of Clinical Endocrinology & Metabolism, 83, 1033-1036.
http://dx.doi.org/10.1210/jc.83.3.1033
[13]
Bassett, M.H., White, P.C. and Rainey, W.E. (2004) The regulation of aldosterone synthase expression. Molecular and Cellular Endocrinology, 217, 67-74.
http://dx.doi.org/10.1016/j.mce. 2003.10.011
[14]
Ulick, S. (1976) Diagnosis and nomenclature of the disorders of the terminal portion of the aldosterone biosynthetic pathway. The Journal of Clinical Endocrinology & Metabolism, 43, 92-96.
http://dx.doi.org/10.1210/jcem-43-1-92
[15]
Collinet, E., Pelissier, P., Richard, O., Gay, C., Pugeat, M., Morel, Y. and Stephan, J.L. (2012) Four cases of aldosterone synthase deficiency in childhood. Archives of Pediatrics, 19, 1191-1195.
http://dx.doi.org/10.1016/j.arcped.2012.08.018
[16]
Pearse, D.D., Tian, R., Nigro, J., Iorgulescu, J.B., Puzis, L. and Jaimes, E.A. (2008) Angiotensin II increases the expression of the transcription factor ETS-1 in mesangial cells. American Journal of Physiology. Renal Physiology, 294, 1094-1100.
http://dx.doi.org/10.1152/ajprenal.00458.2007
[17]
Mezzano, S.A., Ruiz-Ortega, M. and Egido, J. (2001) Angiotensin II and renal fibrosis. Hypertension, 38, 635-638. http://dx.doi.org/10.1161/hy09t1.094234
[18]
Jessen, C.L., Christensen, J.H., Birkebaek, N.H. and Ritting, S. (2012) Homozygosity for a mutation in the CYP11B2 gene in an infant with congenital corticosterone methyl oxidase deficiency type II. Acta Paediatrica, 101, 519-525.
http://dx.doi.org/10.1111/j.1651-2227.2012.02823.x